|
|
||||||||
-Adrenoceptor-mediated cell signaling in the neonatal
heart and liver: responses to terbutaline
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710
Terbutaline, a
2-adrenoceptor (
2-AR) agonist, is a
widely used tocolytic that also crosses the placenta to stimulate fetal
-ARs. The current study examines the effects of terbutaline
administered to neonatal rats. Terbutaline (10 mg/kg sc) given on
postnatal day (PN) 2-5 or
PN 11-14 elicited significant downregulation of both
cardiac and hepatic
-ARs, with a much greater effect in the liver.
Despite the reduction in cardiac
-ARs, receptor desensitization was
absent as evidenced by the maintained ability of isoproterenol to
stimulate adenylyl cyclase (AC) in membrane preparations. The underlying mechanism was dissected by using stimulants that operate at
different points in the AC signaling pathway, NaF, forskolin, and
Mn2+. When administered in the early neonatal period,
terbutaline failed to evoke any changes in cardiac AC activity;
however, treatment on PN 11-14 evoked heterologous
sensitization downstream from the receptor, evidenced by increases in
the response to NaF and forskolin. In the liver, neonatal terbutaline
administration elicited a small (
10%) decrease in the AC response
to isoproterenol, an effect much smaller than the downregulation of
-ARs (>40%). In this tissue, desensitization was again offset by
heterologous sensitization of AC signaling. These results indicate
that, in the developing organism,
-AR-mediated cell signaling
responses are maintained in the face of receptor downregulation through heterologous induction of downstream signaling elements. These unique
responses serve to sustain
-AR signaling in the perinatal period.
adenylyl cyclase; liver;
-adrenoceptor; preterm labor; adenosine
3',5'-cyclic monophosphate; terbutaline; development; tocolysis; heart
This article has been cited by other articles:
![]() |
F. Beitzel, M. N. Sillence, and G. S. Lynch beta-Adrenoceptor signaling in regenerating skeletal muscle after beta-agonist administration Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E932 - E940. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Auman, F. J. Seidler, and T. A. Slotkin beta -Adrenoceptor control of G protein function in the neonate: determinant of desensitization or sensitization Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1236 - R1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Auman, F. J. Seidler, C. A. Tate, and T. A. Slotkin Are developing beta -adrenoceptors able to desensitize? Acute and chronic effects of beta -agonists in neonatal heart and liver Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R205 - R217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Garofolo, F. J. Seidler, J. T. Auman, and T. A. Slotkin beta -Adrenergic modulation of muscarinic cholinergic receptor expression and function in developing heart Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2002; 282(5): R1356 - R1363. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |